HUTCHMED (China) Limited (HKG:0013)
24.54
-0.06 (-0.24%)
Jan 21, 2026, 1:35 PM HKT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,811 employees as of December 31, 2024. The number of employees decreased by 177 or -8.90% compared to the previous year.
Employees
1,811
Change (1Y)
-177
Growth (1Y)
-8.90%
Revenue / Employee
2.66M HKD
Profits / Employee
2.06M HKD
Market Cap
20.31B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | 1,280 | 427 | 50.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 24,379 |
| CSPC Pharmaceutical Group | 21,400 |
| WuXi Biologics | 12,575 |
| BeOne Medicines AG | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| Innovent Biologics | 5,659 |
| JD Health International | 3,564 |
| Akeso | 3,035 |
HUTCHMED (China) News
- 7 days ago - HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - GlobeNewsWire
- 13 days ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 13 days ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 13 days ago - HUTCHMED's ESLIM-02 Trial Of Sovleplenib In Warm Autoimmune Hemolytic Anemia Meets Key Goal - Nasdaq
- 14 days ago - HUTCHMED's Sovleplenib Reaches Phase III Goal In Warm Autoimmune Hemolytic Anemia Trial In China - Nasdaq
- 14 days ago - HCM's Sovleplenib Trial Achieves Key Milestone in Treating Autoimmune Hemolytic Anemia - GuruFocus
- 14 days ago - HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - GlobeNewsWire
- 15 days ago - HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer - Nasdaq